BBOT · ISSUER CIK 1869105
BridgeBio Oncology Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 4 BridgeBio Oncology Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $0.00 of sales on SEC Form 4.
↗4 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. No open-market sales in the window.
$0.00Insider buying
$0.00Insider selling
$0.00Net open-market
Oct 23, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 23, 202616:15 | Oct 21, 2026 | BBOT | Principal Accounting Officer | F · Tax | $2.68 | −203 | 13,812 | -1% | $544.04 | ||
| Oct 5, 202616:14 | Oct 1, 2026 | BBOT | Principal Accounting Officer | F · Tax | $3.94 | −126 | 14,015 | -1% | $496.44 | ||
| Oct 5, 202616:13 | Oct 1, 2026 | BBOT | COO & Principal Financial Ofcr | F · Tax | $3.94 | −343 | 14,152 | -2% | $1K | ||
| Oct 5, 202616:12 | Oct 1, 2026 | BBOT | President and CEO, Director | F · Tax | $3.94 | −1,047 | 43,529 | -2% | $4K | ||
| Oct 5, 202616:11 | Oct 1, 2026 | BBOT | Chief Med & Dev Officer | F · Tax | $3.94 | −1,047 | 43,529 | -2% | $4K | ||
| Sep 14, 202616:24 | Sep 10, 2026 | BBOT | Principal Accounting Officer | F · Tax | $5.52 | −203 | 14,141 | -1% | $1K | ||
| Sep 14, 202616:24 | Sep 10, 2026 | BBOT | Principal Accounting Officer | A · Grant | — | +9,038 | 14,344 | +170% | — |